/C O R R E C T I O N -- Shenzhen Beike Biotechnology Co. Ltd./
In the news release, "Beike Biotech Launches New International Stem Cell
Venture," issued earlier today by Shenzhen Beike Biotechnology Co. Ltd. over
PR Newswire, we are advised by the company that the first sentence of the
second paragraph should read, "Beike's stem cells have been shown to be safe
and effective in therapies based on direct clinical observation in the
hospital setting," rather than, "In China, Beike's use of cord blood and
tissue-derived stem cells is approved by the Chinese Ministry of Health as a
Class 3 medical therapy for numerous clinical applications," as originally
issued inadvertently.
